Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events

Melody El Chemaly, V. E. McGilligan, Mark Gibson, Matthias Clauss, Steven Watterson, H. Denis Alexander, AJ Bjourson, Aaron Peace

Research output: Contribution to journalArticle

8 Downloads (Pure)

Abstract

Summary Tumour necrosis factor alpha converting enzyme (TACE/ADAM17) is a member of the A disintegrin and metalloproteinase (ADAM) family of ectodomain shedding proteinases. It regulates many inflammatory processes by cleaving several transmembrane proteins, including tumour necrosis factor alpha (TNFalpha) and its receptors tumour necrosis factor alpha receptor 1 and tumour necrosis factor alpha receptor 2. There is evidence that TACE is involved in several TACE inflammatory diseases, such as ischaemia, heart failure, arthritis, atherosclerosis, diabetes and cancer as well as neurological and immune diseases. This review summarizes the latest discoveries regarding the mechanism of action and regulation of TACE. It also focuses on the role of TACE in atherosclerosis and coronary artery disease (CAD), highlighting clinical studies that have investigated its expression and protein activity. The multitude of substrates cleaved by TACE make this enzyme an attractive target for therapy and a candidate for biomarker research and development in CAD.
Original languageEnglish
Article numberACVD-1047
Pages (from-to)700-711
Number of pages12
JournalArchives of Cardiovascular Diseases
Volume110
Issue number12
Early online date31 Oct 2017
DOIs
Publication statusE-pub ahead of print - 31 Oct 2017

Keywords

  • Atherosclerosis, Transmembrane proteins, TNFα, Biomarker, TACE

Fingerprint Dive into the research topics of 'Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events'. Together they form a unique fingerprint.

  • Cite this